Literature DB >> 35714271

Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.

Mohammad Shoushtari1, Farzin Roohvand1, Mostafa Salehi-Vaziri2, Arash Arashkia1, Hasan Bakhshi3, Kayhan Azadmanesh1.   

Abstract

Flaviviruses are arthropod-borne viruses (arboviruses) that have been recently considered among the significant public health problems in defined geographical regions. In this line, there have been vaccines approved for some flaviviruses including dengue virus (DENV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and tick-borne encephalitis virus (TBEV), although the efficiency of such vaccines thought to be questionable. Surprisingly, there are no effective vaccine for many other hazardous flaviviruses, including West Nile and Zika viruses. Furthermore, in spite of approved vaccines for some flaviviruses, for example DENV, alternative prophylactic vaccines seem to be still needed for the protection of a broader population, and it originates from the unsatisfying safety, and the efficacy of vaccines that have been introduced. Thus, adenovirus vector-based vaccine candidates are suggested to be effective, safe, and reliable. Interestingly, recent widespread use of adenovirus vector-based vaccines for the COVID-19 pandemic have highlighted the importance and feasibility of their widespread application. In this review, the applicability of adenovirus vector-based vaccines, as promising approaches to harness the diseases caused by Flaviviruses, is discussed.

Entities:  

Keywords:  Adenovirus; Flavivirus; arbovirus; vaccine; vector-borne diseases

Mesh:

Substances:

Year:  2022        PMID: 35714271      PMCID: PMC9481145          DOI: 10.1080/21645515.2022.2079323

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  131 in total

Review 1.  Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.

Authors:  Nasser Hashemi Goradel; Nasir Mohajel; Ziba Veisi Malekshahi; Samira Jahangiri; Masoud Najafi; Bagher Farhood; Keywan Mortezaee; Babak Negahdari; Arash Arashkia
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

Review 2.  Adenovirus protein IX: a new look at an old protein.

Authors:  Robin J Parks
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

3.  Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice.

Authors:  Whitney R Baldwin; Jill A Livengood; Holli A Giebler; Janae L Stovall; Karen L Boroughs; Stephanie Sonnberg; Kelly J Bohning; Elizabeth A Dietrich; Yee Tsuey Ong; Hoang K Danh; Hetal K Patel; Claire Y-H Huang; Hansi J Dean
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

4.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

5.  Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Authors:  Philippe Desprès; Chantal Combredet; Marie-Pascale Frenkiel; Clarisse Lorin; Michel Brahic; Frédéric Tangy
Journal:  J Infect Dis       Date:  2004-12-10       Impact factor: 5.226

6.  Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.

Authors:  K M Hehir; D Armentano; L M Cardoza; T L Choquette; P B Berthelette; G A White; L A Couture; M B Everton; J Keegan; J M Martin; D A Pratt; M P Smith; A E Smith; S C Wadsworth
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.

Authors:  Bárbara R Quinan; Inge E A Flesch; Tânia M G Pinho; Fabiana M Coelho; David C Tscharke; Flávio G da Fonseca
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

8.  An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.

Authors:  Saima Khanam; Pilankatta Rajendra; Navin Khanna; Sathyamangalam Swaminathan
Journal:  BMC Biotechnol       Date:  2007-02-15       Impact factor: 2.563

Review 9.  Zika Virus Pathogenesis: A Battle for Immune Evasion.

Authors:  Judith Estévez-Herrera; Silvia Pérez-Yanes; Romina Cabrera-Rodríguez; Daniel Márquez-Arce; Rodrigo Trujillo-González; José-David Machado; Ricardo Madrid; Agustín Valenzuela-Fernández
Journal:  Vaccines (Basel)       Date:  2021-03-22

10.  A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses.

Authors:  Natalie A Prow; Liang Liu; Eri Nakayama; Tamara H Cooper; Kexin Yan; Preethi Eldi; Jessamine E Hazlewood; Bing Tang; Thuy T Le; Yin Xiang Setoh; Alexander A Khromykh; Jody Hobson-Peters; Kerrilyn R Diener; Paul M Howley; John D Hayball; Andreas Suhrbier
Journal:  Nat Commun       Date:  2018-03-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.